Monogenetic Disease Therapy Market Report 2026

Monogenetic Disease Therapy Market Overview

• Monogenetic Disease Therapy market size has reached to $28.3 billion in 2025 • Expected to grow to $45.58 billion in 2030 at a compound annual growth rate (CAGR) of 10% • Growth Driver: Rising Adoption Of Precision And Personalized Medicine Is Fueling The Growth Of The Market Due To Demand For Tailored, Mutation-specific, And Highly Effective Treatments. • Market Trend: Advancing Targeted Gene Therapy Protocols To Slow Progression Of Monogenetic Diseases • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Monogenetic Disease Therapy Market?

Monogenetic disease therapy refers to advanced medical treatments developed to target diseases caused by a mutation or defect in a single gene by correcting, replacing, silencing, or compensating for the abnormal gene or its resulting protein function. These therapies include gene therapy, RNA-based treatments, enzyme replacement therapies, and targeted small-molecule drugs, all of which aim to treat the underlying genetic cause rather than only managing the clinical symptoms. The main types of monogenetic disease therapy include pharmacological, surgical, blood transfusion, gene therapies, and other therapy types. Pharmacological therapies refer to treatments using drugs to manage symptoms or modify disease progression in patients with single-gene disorders. These therapies are classified by inheritance patterns such as autosomal and chromosomal. They are applied for diseases including cystic fibrosis, sickle cell anemia, phenylketonuria, and other applications. They are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used by end users including clinics, hospitals, diagnostic centres, home healthcare, and other end users.

What Is The Monogenetic Disease Therapy Market Growth Forecast?

The monogenetic disease therapy market size is expected to see rapid growth in the next few years. It will grow to $45.58 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to growth in Gene Editing platforms, expansion of rare disease pipelines, higher genetic screening rates, increased personalized therapy funding, broader regulatory approvals. Major trends in the forecast period include single gene targeted therapies, gene replacement treatment programs, rna based genetic treatments, rare disease gene correction, precision genetic drug design.

Global Monogenetic Disease Therapy Market Segmentation

1) By Therapy Type: Pharmacological; Surgical; Blood Transfusion; Gene Therapies; Other Therapy Types 2) By Inheritance Pattern: Autosomal; Chromosomal 3) By Application: Cystic Fibrosis; Sickle Cell Anemia; Phenylketonuria; Other Applications 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy 5) By End-Users: Clinics; Hospitals; Diagnostic Centres; Home Healthcare; Other End-Users Subsegments: 1) By Pharmacological: Small Molecule Drugs; Enzyme Replacement Therapies; Protein Replacement Therapies; Immunomodulatory Drugs; Targeted Molecular Therapies 2) By Surgical: Organ Transplant Procedures; Tissue Repair Surgeries; Gene Editing Assisted Surgeries; Minimally Invasive Surgeries; Corrective Surgical Interventions 3) By Blood Transfusion: Red Blood Cell Transfusions; Platelet Transfusions; Plasma Transfusions; Stem Cell Infusions; Autologous Blood Transfusions 4) By Gene Therapies: Ex Vivo Gene Therapy; In Vivo Gene Therapy; Viral Vector Based Gene Therapy; Non Viral Vector Gene Therapy; Genome Editing Based Therapy 5) By Other Therapy Types: Cell Based Therapies; RNA Based Therapies; Protein Based Therapies; Combination Therapies; Experimental Therapies

What Is The Driver Of The Monogenetic Disease Therapy Market?

The rising adoption of precision and personalized medicine is expected to propel the growth of the monogenetic disease therapy market going forward. Precision and personalized medicine is a medical approach that tailors disease prevention, diagnosis, and treatment to an individual’s unique genetic, molecular, or lifestyle characteristics to maximize therapeutic efficacy and minimize adverse effects. The rise of precision and personalized medicine is due to healthcare providers and patients seeking tailored treatments that maximize therapeutic efficacy, minimize adverse effects, and address individual genetic, molecular, or lifestyle characteristics. Monogenetic disease therapy supports precision and personalized medicine by targeting a patient’s specific genetic mutation, enabling highly tailored and effective treatments. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the rising adoption of precision and personalized medicine is driving the growth of the monogenetic disease therapy industry.

Key Players In The Global Monogenetic Disease Therapy Market

Major companies operating in the monogenetic disease therapy market are Pfizer Inc., Sanofi S.A., Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics Inc., Ptc therapeutics inc., Crispr therapeutics ag, CRISPR Therapeutics, Voyager Therapeutics Inc., Oxford Biomedica plc, REGENXBIO INC., Arcturus therapeutics holdings inc., Editas medicine Inc., American Gene Technologies, UniQure NV., MeiraGTx Limited, Prime medicine, Abeona therapeutics Inc., Blue Cross Blue Shield Association, Rocket pharmaceuticals Inc.

Global Monogenetic Disease Therapy Market Trends and Insights

Major companies operating in the monogenetic disease therapy market are focusing on developing innovative gene therapies, such as Duchenne muscular dystrophy (DMD)–targeted protocols, to slow disease progression and improve long-term patient outcomes. Duchenne muscular dystrophy–targeted protocols are structured clinical or therapeutic guidelines specifically designed to diagnose, monitor, and manage patients with Duchenne muscular dystrophy, focusing on slowing disease progression, improving muscle function, and addressing associated complications. For instance, in January 2026, Sarepta Therapeutics Inc, a US-based biopharmaceutical company, launched Elevidys for ambulatory patients aged four and older with DMD, reporting up to a 73% reduction in the rate of functional decline over three years compared with an external control group, highlighting the importance of early intervention to alter disease course and improve quality of life.

What Are Latest Mergers And Acquisitions In The Monogenetic Disease Therapy Market?

In October 2024, Ocuphire Pharma Inc., a US-based clinical-stage ophthalmic biopharmaceutical company, acquired Opus Genetics Inc. for an undisclosed amount. With this acquisition, Ocuphire aimed to create a leading gene therapy franchise by combining its late-stage drug development expertise with Opus Genetics’ pipeline of AAV-based gene therapy candidates for conditions such as Leber congenital amaurosis and other inherited retinal disorders. Opus Genetics Inc. is a US-based clinical-stage gene therapy company specializing in monogenetic disease therapy, focused on developing AAV-based, one-time treatments for rare inherited retinal diseases caused by single-gene mutations.

Regional Insights

North America was the largest region in the monogenetic disease therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Monogenetic Disease Therapy Market?

The monogenetic disease therapy market includes revenues earned by entities through gene replacement therapies, gene editing therapies, RNA-based therapies, cell-based gene therapies, and gene silencing or modulation therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Monogenetic Disease Therapy Market Report 2026?

The monogenetic disease therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the monogenetic disease therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.